COVID-19 positive hearts may be safe for transplantation

A recent study soon to be presented at the American Heart Association (AHA) Scientific Sessions 2022* suggests that hearts from coronavirus disease 2019 (COVID-19)-positive (COVID-19+) donors may be safe for transplantation.

Small case series have shown the success of heart transplantation from COVID-19+ donors, but the impact of COVID-19 status of the donor is not known at a national level. The guidelines from the Heart Failure Society of America, the American College of Cardiology, and AHA for managing heart failure recommend transplantation for those progressing to advanced heart failure (stage D).

Advanced heart failure patients experience severe symptoms such as swelling, fatigue, and shortness of breath. These symptoms interfere with daily activities and may cause recurrent hospital admissions despite optimal medical therapies. According to AHA’s Heart Disease and Stroke Statistics, heart transplant demand has doubled in the last three decades. More than 3000 individuals are now waiting for heart transplantation in the United States (US).

Study: Outcomes of COVID-19 Positive Donor Heart Transplantation in the United States. Image Credit: Maksim Shmeljov / ShutterstockStudy: Outcomes of COVID-19 Positive Donor Heart Transplantation in the United States. Image Credit: Maksim Shmeljov / Shutterstock

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

The study and findings

In the present study, researchers characterized the outcomes of the first COVID-19+ donor heart transplants in the US. They retrospectively analyzed the United Network for Organ Sharing database for adult heart transplants between February 2021 and March 2022. The COVID-19+ positive status of donors was defined as a positive antigen, nucleic acid amplification, or other tests within seven days of transplantation.

The differences in outcomes, such as graft failure, length of stay in the hospital, postoperative complications (dialysis or stroke), and 30-day survival, were assessed using Kaplan-Meier survival estimates and Fisher’s exact test. The present analysis included 3,289 heart transplant cases, including 84 COVID-19+ donors.

Cold ischemic times were similar between COVID-19+ allografts and others. The average length of hospitalization was 15 days for recipients of COVID-19+ allografts compared to 17 days for patients receiving the organ from a non-COVID-19+ donor. Graft rejection was recorded in 2.4% of COVID-19+ allograft recipients compared to 1% in others.

The 30-day survival rate was similar between patients receiving a heart from COVID-19+ donors (96.1%) and non-COVID-19+ donors (97%). The rates of postoperative complications, such as dialysis and stroke, were similar between the two groups. Four recipients of COVID-19+ allografts died, with none from infectious or pulmonary causes. Notably, the use of COVID-19+ allografts increased throughout the study.

Conclusions

The short-term outcomes of transplant cases receiving a heart from COVID-19+ donors are encouraging. The study provided preliminary evidence that heart transplantation could be safe using appropriate allografts from COVID-19+ donors. The small sample size may limit the impact of the findings, and the study may be underpowered to identify differences in heart transplant experiences. Further monitoring is warranted for long-term outcomes and potential outcomes.

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

Journal references:

Article Revisions

  • May 17 2023 - The preprint preliminary research paper that this article was based upon was accepted for publication in a peer-reviewed Scientific Journal. This article was edited accordingly to include a link to the final peer-reviewed paper, now shown in the sources section.
Tarun Sai Lomte

Written by

Tarun Sai Lomte

Tarun is a writer based in Hyderabad, India. He has a Master’s degree in Biotechnology from the University of Hyderabad and is enthusiastic about scientific research. He enjoys reading research papers and literature reviews and is passionate about writing.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Sai Lomte, Tarun. (2023, May 17). COVID-19 positive hearts may be safe for transplantation. News-Medical. Retrieved on November 22, 2024 from https://www.news-medical.net/news/20221101/COVID-19-positive-hearts-may-be-safe-for-transplantation.aspx.

  • MLA

    Sai Lomte, Tarun. "COVID-19 positive hearts may be safe for transplantation". News-Medical. 22 November 2024. <https://www.news-medical.net/news/20221101/COVID-19-positive-hearts-may-be-safe-for-transplantation.aspx>.

  • Chicago

    Sai Lomte, Tarun. "COVID-19 positive hearts may be safe for transplantation". News-Medical. https://www.news-medical.net/news/20221101/COVID-19-positive-hearts-may-be-safe-for-transplantation.aspx. (accessed November 22, 2024).

  • Harvard

    Sai Lomte, Tarun. 2023. COVID-19 positive hearts may be safe for transplantation. News-Medical, viewed 22 November 2024, https://www.news-medical.net/news/20221101/COVID-19-positive-hearts-may-be-safe-for-transplantation.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Could vitamin D help COVID-19 patients? Meta-analysis highlights potential ICU reduction